[1]
|
D. G. Pfister, S. A. Laurie, G. S. Weinstein, W. M. Mendenhall, D. J. Adelstein, K. K. Ang, et al., “American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer,” Journal of Clinical Oncology, Vol. 24, No. 22, 2006, pp. 3693-3704.
doi:10.1200/JCO.2006.07.4559
|
[2]
|
E. Cellai, P. Frata, S. M. Magrini, F. Paiar, R. Barca, S. Fondelli, et al., “Radical Radiotherapy for Early Glottic Cancer: Results in a Series of 1087 Patients from Two Italian Radiation Oncology Centers. I. The Case of T1N0 Disease,” International Journal of Radiation Oncology *Biology*Physics, Vol. 63, No. 5, 2005, pp. 1378-1386.
doi:10.1016/j.ijrobp.2005.05.018
|
[3]
|
P. Frata, E. Cellai, S. M. Magrini, B. Bonetti, E. Vitali, S. Tonoli, et al., “Radical Radiotherapy for Early Glottic Cancer: Results in a Series of 1087 Patients from Two Italian Radiation Oncology Centers. II. The Case of T2N0 Disease,” International Journal of Radiation Oncology *Biology*Physics, Vol. 63, No. 5, 2005, pp. 1378-1394.
doi:10.1016/j.ijrobp.2005.05.013
|
[4]
|
L. H. Sobin and C. Wittekind, “International Union against Cancer (UICC) TNM Classification of Malignant Tumours,” 6th Edition, Wiley, New York, 2002.
|
[5]
|
Eastern Cooperative Oncology Group (ECOG) Performance Status.
|
[6]
|
A. H. Calvert, D. R. Newell, L. A. Gumbrell, S. O’Reilly, M. Burnell, F. E. Boxall, et al., “Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,” Journal of Clinical Oncology, Vol. 7, No. 11, 1989, pp. 1748-1756.
|
[7]
|
National Cancer Institute, “Common Terminology Criteria for Adverse Events v4.0,”
http://ctep.cancer.gov/protocolDeve lopment/electronicapp- lications/ctc.htm
|
[8]
|
R Foundation for Statistical Computing, “Free Software,” http://www.r-project.org
|
[9]
|
E. L. Kaplan and P. Meier, “Non-Parametric Estimation from Incomplete Observations,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:10.1080/01621459. 1958.10501452
|
[10]
|
T. Akimoto, T. Nonaka, Y. Kitamoto, H. Ishikawa, H. Ninomiya, K. Chikamatsu, et al., “Radiation Therapy for T2N0 Laryngeal Cancer: A Retrospective Analysis for the Impact of Concurrent Chemotherapy on Local Control,” International Journal of Radiation Oncology*Biology* Physics, Vol. 64, No. 4, 2006, pp. 995-1001.
doi:10.1016/j.ijrobp.2005.10.003
|
[11]
|
Y. Kumamoto, M. Masuda, Y. Kuratomi, S. Toh, A. Shinokuma, K. Chujo, et al., “FAR” Chemoradiotherapy Improves Laryngeal Preservation Rates in Patients with T2N0 Glottic Carcinoma,” Head & Neck, Vol. 24, No. 7, 2002, pp. 637-642. doi:10.1002/hed.10114
|
[12]
|
Y. Itoh and N. Fuwa, “Retrospective Analysis: Concurrent Chemoradiotherapy Using Protracted Continuous Infusion of Low-Dose Cisplatin and 5-Fluorouracil for T2N0 Glottic Cancer,” Radiation Medicine, Vol. 24, No. 4, 2006, pp. 277-281. doi:10.1007/s11604-005-1517-1
|
[13]
|
M. Nakayama, K. Hayakawa, M. Okamoto, Y. Niibe, H. Ishiyama and S. Kotani, “Phase I/II Trial of Concurrent Use of S-1 and Radiation Therapy for T2 Glottic Cancer,” Japanese Journal of Clinical Oncology, Vol. 40, No. 10, 2010, pp. 921-926. doi:10.1093/jjco/hyq077
|
[14]
|
A. B. Karim, J. H. Kralendonk, L. Y. Yap, K. H. Njo, A. H. Tierie, R. M. Tiwari, et al., “Heterogeneity of Stage II Glottic Carcinoma and Its Therapeutic Implications,” International Journal of Radiation Oncology*Biology*Physics, Vol. 13, No. 3, 1987, pp. 313-317.
doi:10.1016/0360-3016(87)90004-6
|
[15]
|
S. P. Reddy, R. L. Hong, S. Nagda and B. Emami, “Effect of Tumor Bulk on Local Control and Survival of Patients with T1 Glottic Cancer: A 30-Year Experience,” International Journal of Radiation Oncology*Biology*Physics, Vol. 69, No. 5, 2007, pp. 1389-1394.
doi:10.1016/j.ijrobp.2007.05.077
|
[16]
|
E. D. McCoul and G. Har-El, “Meta-Analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma,” JAMA Otolaryngology—Head & Neck Surgery, Vol. 135, No. 5, 2009, pp. 479-486.
doi:10.1001/archoto.2009.47
|
[17]
|
H. Haugen, K. A. Johansson and C. Mercke, “Hyperfractionated-Accelerated or Conventionally Fractionated Radiotherapy for Early Glottic Cancer,” International Journal of Radiation Oncology*Biology*Physics, Vol. 52, No. 1, 2002, pp. 109-119.
doi:10.1016/S0360-3016(01)01812-0
|
[18]
|
H. Tsuji, T. Kiba, M. Nagata, T. Inoue, H. Yukawa, T. Yamashita, et al., “A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma,” Oncology, Vol. 71, No. 5-6, 2006, pp. 369-373.
doi:10.1159/000108385
|